

SERUM EXCHANGE #581 AUGUST 4, 2021

| | |
|------|-------------|
| Sera | 1317 - 1320 |
|------|-------------|

The results for Serum Exchange #581 are summarized in Tables 19 - 26 and individual listing of results are shown in tables 27 - 40. Sera strongly

positive to A29, A66, B7, B27, and B18 antibodies, as well as sera with strong reactivity to DR and DQ antibodies were examined in this study.

| 1317 | method | #labs | A29 | A1 | A36 | B42 | B56 | B55 | B53 | B35 | B49 | B75 | A30 | A80 | A43 | B50 | B62 | B71 | B72 | B70 | B77 | B63 | A26 | B67 | B54 | B7 | B82 | A2 | A68 |
|----------|---------|-------|--------------|------|--------|--------|------|------|------|------|------|------|-----|------|------|------|------|------|------|---------|---------|-----|-----|-----|-----|-----|-----|-----|-----|
| class I | NIH-Std | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 100% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | 50% | | | | | | | | | 50% | | | | | | | | | |
| | C1q | 3 | 100% | 100% | 67% | | | | | | | 33% | 33% | | | | | | | | | | | | | | | | |
| | PRA | 3 | 67% | 67% | 67% | 67% | 67% | 33% | 67% | 67% | 67% | 33% | 67% | 67% | 33% | 33% | 67% | 67% | 67% | | 33% | 67% | 67% | 67% | 33% | 33% | 33% | 33% | 33% |
| | SAB | 23 | 100% | 100% | 100% | 96% | 100% | 96% | 100% | 100% | 100% | 100% | 83% | 100% | 100% | 100% | 100% | 100% | 100% | | 100% | 96% | 96% | 96% | 83% | 78% | 70% | 78% | 65% |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1317 | method | #labs | B58 | B57 | Cw10 | B41 | B39 | B46 | B51 | B78 | A69 | A33 | B81 | A3 | B44 | Cw15 | Cw2 | Cw9 | Cw4 | A31 | A74 | A34 | B59 | A23 | B76 | B37 | B52 | | |
| | PRA | 3 | 67% | 33% | 33% | 33% | 33% | | | | | | | 33% | 33% | 33% | 33% | | | | | | | | | | | | |
| | SAB | 23 | 65% | 61% | 61% | 39% | 22% | 83% | 78% | 74% | 70% | 65% | 65% | | | | 4% | 65% | 61% | 57% | 57% | 48% | 35% | 26% | 26% | 17% | 13% | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1317 | method | #labs | NEG | DR14 | DR1403 | DR1404 | DR11 | DR12 | DR13 | DR17 | DR18 | DR8 | DR9 | DR53 | DR10 | DR52 | DR7 | DQ5 | DQ2 | DQA1*05 | DQA1*01 | DR3 | | | | | | | |
| class II | C1q | 2 | 100% | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | PRA | 3 | | 67% | 33% | 33% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 33% | 67% | 67% | | | | | | | | | | | | | |
| | SAB | 21 | | 95% | 14% | 14% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 90% | 86% | 81% | 38% | 38% | 24% | 19% | 10% | 10% | | | | | | | |

Serum 1317. Strong ant-A29 (16891) reactivity was detected in this sample by all methods. Additional reactivity to A1 (10714) and A36 (10150), along with reactivity to a number of 5C and 7C specificities was reported by various methods. PRA and SAB also reported C-locus reactivity in this sample.

Class II reactivity was also detected, with PRA and SAB labs reporting reactivity to a number of DR specificities, including anti-DR14 (6406), -DR11 (5486), -DR9 (4258), -DR13 (4896), -DR17 (3595), and -DR18 (3477) reactivity. This sample was class II negative by C1q.

*(median MFI)

| 1318 | method | #labs | A66 | A6601 | A6602 | A25 | A26 | A34 | A43 | A11 | A1101 | A1102 | A32 | A33 | A68 | A3 | A30 | A31 | A29 | B7 | B8 |
|---------|---------|-------|--------------|-------|-------|------|------|------|------|-----|-------|-------|------|------|------|------|------|------|-----|------|------|
| class I | NIH-Std | 1 | no consensus | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 50% | | | | | | | | | | | | | | | | | | |
| | C1q | 3 | 67% | | | 33% | 33% | 33% | 33% | 33% | | | | | | | | | | | |
| | PRA | 3 | 67% | | | 67% | 67% | 67% | 33% | 67% | | | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% |
| | SAB | 23 | 87% | 26% | 26% | 100% | 100% | 100% | 100% | 91% | 22% | 22% | 100% | 100% | 100% | 100% | 100% | 100% | 96% | 100% | 100% |

| 1318 | method | #labs | B81 | B8101 | B703 | A69 | A36 | A74 | A80 | A1 | B41 | B42 | B48 | B73 | B40 | B60 | Cw7 | Cw6 | Cw18 | B15 | B75 |
|------|--------|-------|-----|-------|------|------|------|------|------|-----|------|------|------|-----|-----|------|-----|-----|------|-----|-----|
| | PRA | 3 | 67% | | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | | 33% | | | 33% | |
| | SAB | 23 | 91% | 22% | 17% | 100% | 100% | 100% | 100% | 96% | 100% | 100% | 100% | 96% | | 100% | 83% | 83% | 83% | | 65% |

| 1318 | method | #labs | B27 | B38 | B61 | B67 | B39 | Cw10 | Cw3 | Cw12 | Cw2 | Cw9 | Cw15 | B44 | B57 | B58 | B82 | B77 | B18 | B49 | B50 |
|------|--------|-------|-----|-----|-----|-----|-----|------|-----|------|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|
| | PRA | 3 | 33% | | | | 33% | | 33% | 33% | 33% | | 33% | 33% | 33% | 33% | 33% | | | | |
| | SAB | 23 | | 57% | 57% | 52% | 48% | 52% | | 13% | 13% | 39% | | 17% | 4% | | | 17% | 13% | 13% | 13% |

| 1318 | method | #labs | DR8 | DR11 | DR13 | DQ7 | DQ8 | DQ9 | DR4 | DR16 | DQ6 | DR53 | DQA1*03 | DQA1*05 | DR52 | DPw5 | DQ4 | DQA1*06 |
|----------|--------|-------|------|------|------|------|------|------|------|------|-----|------|---------|---------|------|------|-----|---------|
| class II | C1q | 2 | 100% | 100% | 100% | 100% | 50% | 50% | | | | | | | | | | |
| | PRA | 3 | 67% | 67% | 33% | 67% | 67% | 67% | 67% | 33% | 33% | | 33% | 33% | | | | |
| | SAB | 21 | 100% | 100% | 90% | 100% | 100% | 100% | 100% | 76% | 57% | 52% | 29% | 24% | 29% | 24% | 24% | 24% |

| 1318 | method | #labs | DP14 | DP17 | DPA1*02 | DR1404 | DP9 | DQA1*01 | DR15 | DP10 | DP11 | DP13 | DP15 | DPw1 | DQ3 | DR12 | DR14 | DR51 |
|------|--------|-------|------|------|---------|--------|-----|---------|------|------|------|------|------|------|-----|------|------|------|
| | SAB | 21 | 19% | 19% | 19% | 19% | 14% | 14% | 14% | 10% | 10% | 10% | 10% | 10% | 10% | 10% | 10% | 10% |

Serum 1318. Strong anti-A66 (13756) reactivity was detected in this sample by all methods. Strong reactivity to other class I antibodies was also reported by various methods, including reactivity to A25 (14035), A26 (12971), A34 (11926), A43 (10310), A11 (9787), and A32 (9842). C-locus reactivity was reported as well by PRA and SAB.

Strong class II reactivity was also reported in this sample, with C1q, PRA, and SAB labs reporting anti-DR8 (15074), -DR11 (15231), -DR13 (16728), -DQ7 (17260), -DQ8 (14994), and -DQ9 (14429) reactivity. Strong DQA1*03 (14493), DQA1*05 (18749), and DQA1*06 (19013) reactivity was also reported by some PRA and SAB labs.

*(median MFI)

| 1319 | method | #labs | B27 | B2708 | B2705 | B7 | B42 | B55 | B56 | B60 | B61 | B48 | B81 | B8101 | B54 | B67 | B73 | B82 | B8201 | B57 | |
|---------|---------|-------|--------------|-------|-------|------|------|------|------|------|------|-----|-----|-------|------|------|------|-----|-------|------|--|
| class I | NIH-Std | 1 | no consensus | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 100% | | | 100% | 100% | 50% | 50% | 50% | 50% | 50% | 50% | | | | | | | | |
| | C1q | 3 | 67% | 33% | 33% | 100% | 100% | 67% | 100% | 67% | 67% | 67% | 67% | 33% | 100% | 100% | 100% | 67% | 33% | | |
| | PRA | 3 | 67% | 33% | | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | | 67% | 67% | 67% | 67% | 33% | 67% | |
| | SAB | 23 | 91% | 39% | 26% | 100% | 100% | 100% | 100% | 100% | 100% | 91% | 91% | 26% | 100% | 100% | 100% | 96% | | 100% | |

| 1319 | method | #labs | B63 | B46 | B13 | B47 | A6602 | B703 | Cw15 | Cw2 | Cw9 | Cw10 | Cw3 | Cw1 | Cw14 | Cw16 | A3 | A25 | B64 | |
|------|--------|-------|------|-----|------|------|-------|------|------|-----|-----|------|-----|-----|------|------|-----|-----|-----|--|
| | C1q | 3 | | | | | 33% | | | | | | | | | | | | | |
| | PRA | 3 | 67% | | 67% | 67% | | 33% | 33% | | | | 33% | | | | 33% | | | |
| | SAB | 23 | 100% | 83% | 100% | 100% | 52% | 13% | 83% | 96% | 91% | 91% | 4% | 35% | 35% | 22% | | 22% | 13% | |

| 1319 | method | #labs | NEG | DQ8 | DQ7 | DQ9 | DQA1*03 | DQA1*05 | DQA1*06 | DQ3 |
|----------|--------|-------|------|-----|-----|-----|---------|---------|---------|-----|
| class II | C1q | 2 | 100% | | | | | | | |
| | PRA | 3 | 33% | 33% | 33% | 33% | 33% | | | |
| | SAB | 19 | 11% | 58% | 52% | 47% | 42% | 21% | 16% | 11% |

Serum 1319. Strong anti-B27 (16456) and –B7 (16566) reactivity was detected in this sample by all methods. In addition, AHG, C1q, PRA, and SAB reported strong reactivity to B42 (16425), B55 (17842), B56 (16704), B60 (13307), B61(13223), B48 (11049), and B81 (17265). Allele specific B*27:08 and B*27:05 reactivity was reported by various methods. In addition, PRA and SAB reported reactivity to a number of C-locus specificities, including Cw15

and Cw3 (Cw9, Cw10).

The reporting of class II reactivity in this sample was mixed, with ≤ 58% of Luminex-SAB and PRA labs reporting reactivity to DQ8 (6662), DQ9 (4812), DQ7 (1212), and DQA1*03 (10576). Three SAB labs, 1 PRA lab, and 2 C1q labs reported this sample as negative for class II.

*(median MFI)

| 1320 | method | #labs | B18 | B51 | B8 | B35 | B78 | B7801 | A23 | A24 | A2403 | A3 | B38 | B37 | B64 | B65 | B44 | B53 | B54 | B41 | B45 | B59 | B52 | B62 |
|---------|---------|-------|--------------|------|------|------|------|-------|------|------|-------|-------|-------|-------|-------|------|------|------|------|-----|------|-------|-------|------|
| class I | NIH-Std | 1 | no consensus | | | | | | | | | | | | | | | | | | | | | |
| | AHG | 2 | 100% | 50% | 50% | 50% | | | | | | 50% | 50% | 50% | | | 50% | | | 50% | | | | |
| | C1q | 3 | 100% | 100% | 33% | 33% | 33% | | 33% | 33% | | | | | 100% | 33% | | 33% | 33% | | | | | |
| | PRA | 3 | 67% | 67% | 67% | 67% | 67% | | 33% | 33% | 33% | 33% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 33% | 67% | 67% | 67% | 67% |
| | SAB | 22 | 100% | 100% | 100% | 100% | 96% | 17% | 100% | 100% | 30% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 78% | 100% | 100% | 100% | 100% |
| 1320 | method | #labs | B71 | B72 | B77 | B75 | B76 | A2 | A33 | A68 | A69 | B73 | B39 | B3901 | B55 | B82 | B67 | A34 | A25 | A26 | A66 | A6601 | A6602 | |
| | PRA | 3 | 67% | 67% | 67% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | | 33% | 33% | 67% | 33% | 33% | 33% | 33% | 33% | | | |
| | SAB | 22 | 100% | 96% | 100% | 100% | 100% | 100% | 100% | 100% | 96% | 96% | 91% | 26% | 91% | 91% | 87% | 91% | 78% | 61% | 70% | 22% | 26% | |
| 1320 | method | #labs | A1 | B42 | B7 | B61 | A29 | B48 | B50 | B60 | B81 | B8101 | B8201 | B27 | B2708 | A203 | B703 | B56 | B13 | B49 | Bw6 | A2C | B8C | Bw4 |
| | PRA | 3 | 33% | 33% | 33% | 33% | | | 33% | 33% | 33% | | | | | 33% | 33% | | | | | | | |
| | SAB | 22 | 83% | 83% | 83% | 78% | 74% | 70% | 65% | 65% | 65% | 13% | 13% | 39% | 22% | 22% | 4% | 39% | 35% | 22% | 22% | 13% | 13% | 13% |

| 1320 | method | #labs | DQ4 | DQ6 | DQ5 | DR1 | DR10 | DR103 | DR11 | DR12 | DR13 | DR14 | DR1404 | DR1403 | DR8 | DR9 | DR15 | DR16 | DR51 | DR52 | DR53 |
|----------|--------|-------|------|---------|---------|---------|---------|---------|---------|------|------|------|--------|---------|---------|---------|------|------|------|------|---------|
| class II | C1q | 2 | 67% | 67% | 67% | 67% | 67% | 33% | 67% | 67% | 67% | 33% | | | 67% | 67% | 67% | 67% | 67% | | |
| | PRA | 3 | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 67% | 33% | 33% | 67% | 67% | 67% | 67% | 67% | 67% | 33% |
| | SAB | 21 | 100% | 100% | 95% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 19% | 14% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| 1320 | method | #labs | DR17 | DR18 | DR7 | DPw5 | DPw1 | DPw4 | DP401 | DR4 | DQ7 | DP11 | DP13 | DP19 | DP15 | DP17 | DP23 | DPw2 | DP28 | DP9 | DPA1*02 |
| | PRA | 3 | 67% | 67% | 67% | 33% | 33% | 33% | | 33% | 33% | | | | | | | | | | |
| | SAB | 21 | 100% | 100% | 100% | 100% | 95% | 86% | 29% | 81% | 48% | 100% | 100% | 90% | 81% | 76% | 76% | 76% | 71% | 38% | 38% |
| 1320 | method | #labs | DQ2 | DQA1*05 | DQA1*01 | DQA1*04 | DQA1*03 | DQA1*06 | DQA1*02 | DQ8 | DPw3 | DPw6 | DP14 | DPA1*01 | DPA1*04 | DPA1*03 | DQ9 | DP18 | DP20 | DP10 | DR3 |
| | PRA | 3 | 33% | 33% | 33% | 33% | 33% | 33% | 33% | | | | | | | | | | | | |
| | SAB | 21 | 29% | 67% | 43% | 38% | 24% | 33% | 5% | 38% | 38% | 33% | 33% | 33% | 33% | 14% | 33% | 29% | 29% | 14% | 10% |

Serum 1320. Strong class I and class II reactivity was detected in this sample, including anti-B18 (19769) reactivity which was reported by all methods. Additional reactivity to B38 (7158), B64 (14057), B65 (11095), B44 (4848), and B45 (6471), along with reactivity to a number of 1C, 5C, and 7C specificities was reported by various methods.

Reactivity to a number of DR, DQ, and DP antibodies was reported as well by C1q, PRA, and SAB. This included strong reactivity to DR15 (21159), DR16 (20905), DR51 (22239), DP5 (10532), DP1 (8924), DP4 (DP401) (8836), DP13 (8400), DQ4 (15638), DQ5 (22118), and DQ6 (22414).

*(median MFI)

NEXT MAILING DATE: October 6, 2021

Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed

Table 19. Summary of the 581st Serum Exchange (Serum #1317-1320) by NIH-Standard - class I

| Method: NIH-Standard | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 1 typing Labs | | | 1 typing Labs | | | 1 typing Labs | | | 1 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| no consensus | | | no consensus | | | no consensus | | | no consensus | | |

Table 20. Summary of the 581st Serum Exchange (Serum #1317-1320) by Antiglobulin - class I

| Method: Antiglobulin | | | | | | | | | | | |
|-----------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | | 2 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| A29 | 100% | 100% | A66 | 50% | 100% | B27 | 100% | 100% | B18 | 100% | 100% |
| A36 | 50% | 100% | | | | B42 | 100% | 100% | A3 | 50% | 100% |
| B42 | 50% | 100% | | | | B7 | 100% | 100% | B35 | 50% | 100% |
| B49 | 50% | 100% | | | | B48 | 50% | 100% | B37 | 50% | 100% |
| B53 | 50% | 100% | | | | B56 | 50% | 100% | B38 | 50% | 100% |
| B56 | 50% | 100% | | | | B60 | 50% | 100% | B41 | 50% | 100% |
| B70 | 50% | 100% | | | | B61 | 50% | 100% | B44 | 50% | 100% |
| B55 | 50% | 88% | | | | B81 | 50% | 100% | B51 | 50% | 100% |
| B35 | 50% | 83% | | | | B55 | 50% | 88% | B8 | 50% | 100% |
| A1 | 50% | 80% | | | | | | | | | |

Table 21. Summary of the 581st Serum Exchange (Serum #1317-1320) by C1q - class I

| Method: C1q | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| A1 | 100% | 100% | A66 | 67% | 100% | B42 | 100% | 100% | B18 | 100% | 100% |
| A29 | 100% | 100% | A11 | 33% | 100% | B54 | 100% | 100% | B51 | 100% | 100% |
| A36 | 67% | 100% | A25 | 33% | 100% | B56 | 100% | 100% | B64 | 100% | 100% |
| A30 | 33% | 100% | A26 | 33% | 100% | B67 | 100% | 100% | A23 | 33% | 100% |
| B75 | 33% | 100% | A34 | 33% | 100% | B7 | 100% | 100% | A24 | 33% | 100% |
| | | | A43 | 33% | 100% | B73 | 100% | 100% | B35 | 33% | 100% |
| | | | A6601 | 33% | 100% | B27 | 67% | 100% | B53 | 33% | 100% |
| | | | | | | B48 | 67% | 100% | B54 | 33% | 100% |
| | | | | | | B55 | 67% | 100% | B65 | 33% | 100% |
| | | | | | | B60 | 67% | 100% | B78 | 33% | 100% |
| | | | | | | B61 | 67% | 100% | B8 | 33% | 100% |
| | | | | | | B81 | 67% | 100% | | | |
| | | | | | | B82 | 67% | 100% | | | |
| | | | | | | A66 | 33% | 100% | | | |
| | | | | | | A6602 | 33% | 100% | | | |
| | | | | | | B2705 | 33% | 100% | | | |
| | | | | | | B2708 | 33% | 100% | | | |
| | | | | | | B8101 | 33% | 100% | | | |
| | | | | | | B8201 | 33% | 100% | | | |

Table 22. Summary of the 581st Serum Exchange (Serum #1317-1320) by Luminex PRA - class I

| Method: Luminex - PRA | | | | | | | | | | | |
|-----------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| A1 | 67% | 100% | A11 | 67% | 100% | B13 | 67% | 100% | B18 | 67% | 100% |
| A26 | 67% | 100% | A25 | 67% | 100% | B27 | 67% | 100% | B35 | 67% | 100% |
| A29 | 67% | 100% | A26 | 67% | 100% | B42 | 67% | 100% | B37 | 67% | 100% |
| A30 | 67% | 100% | A29 | 67% | 100% | B47 | 67% | 100% | B38 | 67% | 100% |
| A36 | 67% | 100% | A3 | 67% | 100% | B48 | 67% | 100% | B44 | 67% | 100% |
| A80 | 67% | 100% | A30 | 67% | 100% | B54 | 67% | 100% | B45 | 67% | 100% |
| B35 | 67% | 100% | A31 | 67% | 100% | B55 | 67% | 100% | B51 | 67% | 100% |
| B42 | 67% | 100% | A32 | 67% | 100% | B56 | 67% | 100% | B52 | 67% | 100% |
| B49 | 67% | 100% | A33 | 67% | 100% | B57 | 67% | 100% | B53 | 67% | 100% |
| B53 | 67% | 100% | A34 | 67% | 100% | B60 | 67% | 100% | B54 | 67% | 100% |
| B56 | 67% | 100% | A66 | 67% | 100% | B61 | 67% | 100% | B59 | 67% | 100% |
| B58 | 67% | 100% | A68 | 67% | 100% | B63 | 67% | 100% | B62 | 67% | 100% |
| B62 | 67% | 100% | B7 | 67% | 100% | B67 | 67% | 100% | B64 | 67% | 100% |
| B63 | 67% | 100% | B8 | 67% | 100% | B7 | 67% | 100% | B65 | 67% | 100% |
| B67 | 67% | 100% | B81 | 67% | 100% | B73 | 67% | 100% | B71 | 67% | 100% |
| B71 | 67% | 100% | A1 | 33% | 100% | B81 | 67% | 100% | B72 | 67% | 100% |
| B72 | 67% | 100% | A36 | 33% | 100% | B82 | 67% | 100% | B77 | 67% | 100% |
| A2 | 33% | 100% | A43 | 33% | 100% | A3 | 33% | 100% | B78 | 67% | 100% |
| A3 | 33% | 100% | A69 | 33% | 100% | A66 | 33% | 100% | B8 | 67% | 100% |
| A43 | 33% | 100% | A74 | 33% | 100% | B2708 | 33% | 100% | B82 | 67% | 100% |
| A68 | 33% | 100% | A80 | 33% | 100% | B703 | 33% | 100% | A1 | 33% | 100% |
| B39 | 33% | 100% | B15 | 33% | 100% | B8201 | 33% | 100% | A2 | 33% | 100% |
| B41 | 33% | 100% | B27 | 33% | 100% | Cw15 | 33% | 100% | A203 | 33% | 100% |
| B44 | 33% | 100% | B39 | 33% | 100% | Cw3 | 33% | 100% | A23 | 33% | 100% |
| B50 | 33% | 100% | B40 | 33% | 100% | | | | A24 | 33% | 100% |
| B54 | 33% | 100% | B41 | 33% | 100% | | | | A2403 | 33% | 100% |
| B55 | 33% | 100% | B42 | 33% | 100% | | | | A25 | 33% | 100% |
| B57 | 33% | 100% | B44 | 33% | 100% | | | | A26 | 33% | 100% |
| B7 | 33% | 100% | B48 | 33% | 100% | | | | A29 | 33% | 100% |
| B75 | 33% | 100% | B57 | 33% | 100% | | | | A3 | 33% | 100% |
| B77 | 33% | 100% | B58 | 33% | 100% | | | | A33 | 33% | 100% |
| B82 | 33% | 100% | B703 | 33% | 100% | | | | A34 | 33% | 100% |
| Cw10 | 33% | 100% | B73 | 33% | 100% | | | | A66 | 33% | 100% |
| Cw15 | 33% | 100% | B82 | 33% | 100% | | | | A68 | 33% | 100% |
| Cw2 | 33% | 100% | Cw12 | 33% | 100% | | | | A69 | 33% | 100% |

Table 23. Summary of the 581st Serum Exchange (Serum #1317-1320) by Single Antigen - class I

| Method: Luminex - SAB | | | | | | | | | | | |
|-----------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 23 typing Labs | | | 23 typing Labs | | | 23 typing Labs | | | 23 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| A1 | 100% | 100% | A25 | 100% | 100% | B13 | 100% | 100% | A2 | 100% | 100% |
| A29 | 100% | 100% | A26 | 100% | 100% | B42 | 100% | 100% | A23 | 100% | 100% |
| A36 | 100% | 100% | A3 | 100% | 100% | B47 | 100% | 100% | A24 | 100% | 100% |
| A43 | 100% | 100% | A30 | 100% | 100% | B54 | 100% | 100% | A3 | 100% | 100% |
| A80 | 100% | 100% | A31 | 100% | 100% | B55 | 100% | 100% | A33 | 100% | 100% |
| B35 | 100% | 100% | A32 | 100% | 100% | B56 | 100% | 100% | A68 | 100% | 100% |
| B49 | 100% | 100% | A33 | 100% | 100% | B57 | 100% | 100% | B18 | 100% | 100% |
| B50 | 100% | 100% | A34 | 100% | 100% | B60 | 100% | 100% | B35 | 100% | 100% |
| B53 | 100% | 100% | A36 | 100% | 100% | B61 | 100% | 100% | B37 | 100% | 100% |
| B56 | 100% | 100% | A43 | 100% | 100% | B63 | 100% | 100% | B38 | 100% | 100% |
| B62 | 100% | 100% | A68 | 100% | 100% | B67 | 100% | 100% | B44 | 100% | 100% |
| B71 | 100% | 100% | A69 | 100% | 100% | B7 | 100% | 100% | B45 | 100% | 100% |
| B72 | 100% | 100% | A74 | 100% | 100% | B73 | 100% | 100% | B51 | 100% | 100% |
| B75 | 100% | 100% | A80 | 100% | 100% | B82 | 96% | 100% | B52 | 100% | 100% |
| B77 | 100% | 100% | B41 | 100% | 100% | Cw2 | 96% | 38% | B53 | 100% | 100% |
| A26 | 96% | 100% | B42 | 100% | 100% | B27 | 91% | 100% | B54 | 100% | 100% |
| B42 | 96% | 100% | B48 | 100% | 100% | B48 | 91% | 100% | B59 | 100% | 100% |
| B55 | 96% | 100% | B60 | 100% | 100% | B81 | 91% | 100% | B62 | 100% | 100% |
| B63 | 96% | 100% | B7 | 100% | 100% | Cw9 | 91% | 75% | B64 | 100% | 100% |
| B67 | 96% | 100% | B8 | 100% | 100% | Cw10 | 91% | 73% | B65 | 100% | 100% |
| A30 | 83% | 100% | A1 | 96% | 100% | Cw15 | 83% | 100% | B71 | 100% | 100% |
| B46 | 83% | 100% | A29 | 96% | 100% | B46 | 83% | 33% | B75 | 100% | 100% |
| B54 | 83% | 67% | B73 | 96% | 50% | A66 | 65% | 57% | B76 | 100% | 100% |
| B7 | 78% | 80% | A11 | 91% | 100% | A6602 | 52% | 100% | B77 | 100% | 100% |
| A2 | 78% | 68% | B81 | 91% | 100% | B2708 | 39% | 100% | B8 | 100% | 100% |
| B51 | 78% | 40% | A66 | 87% | 100% | Cw1 | 35% | 100% | A69 | 96% | 100% |
| B78 | 74% | 100% | Cw18 | 83% | 100% | Cw14 | 35% | 100% | B72 | 96% | 100% |
| A69 | 70% | 100% | Cw6 | 83% | 100% | B2705 | 26% | 100% | B73 | 96% | 100% |
| B82 | 70% | 100% | Cw7 | 83% | 100% | B8101 | 26% | 100% | B78 | 96% | 100% |
| A33 | 65% | 100% | B75 | 65% | 100% | A25 | 22% | 100% | B39 | 91% | 100% |
| A68 | 65% | 100% | B38 | 57% | 100% | Cw16 | 22% | 100% | B55 | 91% | 100% |
| B58 | 65% | 100% | B61 | 57% | 100% | B703 | 13% | 100% | B82 | 91% | 100% |
| B81 | 65% | 100% | B67 | 52% | 100% | B64 | 13% | 50% | A34 | 91% | 50% |
| Cw9 | 65% | 100% | Cw10 | 52% | 100% | A32 | 9% | 100% | B67 | 87% | 100% |
| B57 | 61% | 100% | B39 | 48% | 100% | B40 | 9% | 100% | A1 | 83% | 100% |

Table 23. Summary of the 581st Serum Exchange (Serum #1317-1320) by Single Antigen - class I

| Method: Luminex - SAB, cont. | | | | | | | | | | | |
|------------------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 23 typing Labs | | | 23 typing Labs | | | 23 typing Labs | | | 23 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| Cw4 | 61% | 100% | Cw9 | 39% | 100% | B52 | 9% | 100% | B42 | 83% | 100% |
| Cw10 | 61% | 50% | A6601 | 26% | 100% | B7C | 9% | 100% | B7 | 83% | 100% |
| A31 | 57% | 100% | A6602 | 26% | 100% | B8201 | 9% | 100% | A25 | 78% | 100% |
| A74 | 57% | 100% | A1101 | 22% | 100% | Cw17 | 9% | 100% | B41 | 78% | 100% |
| A34 | 48% | 100% | A1102 | 22% | 100% | A10C | 4% | 100% | B61 | 78% | 83% |
| B41 | 39% | 100% | B8101 | 22% | 100% | A2C | 4% | 100% | A29 | 74% | 50% |
| B59 | 35% | 100% | B44 | 17% | 100% | B12C | 4% | 100% | B48 | 70% | 100% |
| A23 | 26% | 100% | B703 | 17% | 100% | B15 | 4% | 100% | A66 | 70% | 50% |
| B76 | 26% | 100% | B77 | 17% | 100% | B22 | 4% | 100% | B50 | 65% | 100% |
| B39 | 22% | 100% | B18 | 13% | 100% | B39 | 4% | 100% | B60 | 65% | 100% |
| B37 | 17% | 100% | B49 | 13% | 100% | B58 | 4% | 100% | B81 | 65% | 100% |
| B52 | 13% | 100% | B50 | 13% | 100% | B5C | 4% | 100% | A26 | 61% | 100% |
| A6601 | 9% | 100% | Cw12 | 13% | 100% | B75 | 4% | 100% | B27 | 39% | 100% |
| B27 | 9% | 100% | Cw2 | 13% | 100% | B76 | 4% | 100% | B56 | 39% | 100% |
| B2708 | 9% | 100% | A10C | 9% | 100% | B8 | 4% | 100% | B13 | 35% | 100% |
| B5C | 9% | 100% | A1C | 9% | 100% | B8C | 4% | 100% | A2403 | 30% | 100% |
| B7801 | 9% | 100% | B3901 | 9% | 100% | Bw4 | 4% | 100% | A6602 | 26% | 100% |
| B8101 | 9% | 100% | B47 | 9% | 100% | Bw6 | 4% | 100% | B3901 | 26% | 100% |
| A10C | 4% | 100% | B55 | 9% | 100% | Cw3 | 4% | 100% | A203 | 22% | 100% |
| A1C | 4% | 100% | B62 | 9% | 100% | Cw4 | 4% | 100% | A6601 | 22% | 100% |
| A203 | 4% | 100% | B63 | 9% | 100% | Cw7 | 4% | 100% | B2708 | 22% | 100% |
| A24 | 4% | 100% | A10 | 4% | 100% | | | | B49 | 22% | 100% |
| A2C | 4% | 100% | A19 | 4% | 100% | | | | Bw6 | 22% | 100% |
| A66 | 4% | 100% | A28 | 4% | 100% | | | | B7801 | 17% | 100% |
| B12C | 4% | 100% | A2C | 4% | 100% | | | | A2C | 13% | 100% |
| B13 | 4% | 100% | B12C | 4% | 100% | | | | B8101 | 13% | 100% |
| B15 | 4% | 100% | B13 | 4% | 100% | | | | B8201 | 13% | 100% |
| B21 | 4% | 100% | B27 | 4% | 100% | | | | B8C | 13% | 100% |
| B38 | 4% | 100% | B37 | 4% | 100% | | | | Bw4 | 13% | 100% |
| B3901 | 4% | 100% | B40 | 4% | 100% | | | | B14 | 9% | 100% |
| B4005 | 4% | 100% | B4005 | 4% | 100% | | | | B5C | 9% | 100% |
| B48 | 4% | 100% | B45 | 4% | 100% | | | | Cw18 | 9% | 100% |
| B70 | 4% | 100% | B46 | 4% | 100% | | | | A10C | 4% | 100% |
| B7C | 4% | 100% | B57 | 4% | 100% | | | | A11 | 4% | 100% |
| B8201 | 4% | 100% | B5C | 4% | 100% | | | | A1C | 4% | 100% |

Table 24. Summary of the 581st Serum Exchange (Serum #1317-1320) by C1q - class II

| Method: C1q | | | | | | | | | | | |
|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 2 typing Labs | | | 2 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| NEG | 100% | - | DQ7 | 100% | 100% | NEG | 100% | - | DQ4 | 67% | 100% |
| | | | DR11 | 100% | 100% | | | | DQ5 | 67% | 100% |
| | | | DR13 | 100% | 100% | | | | DQ6 | 67% | 100% |
| | | | DR8 | 100% | 100% | | | | DR1 | 67% | 100% |
| | | | DQ8 | 50% | 100% | | | | DR10 | 67% | 100% |
| | | | DQ9 | 50% | 100% | | | | DR103 | 67% | 100% |
| | | | | | | | | | DR11 | 67% | 100% |
| | | | | | | | | | DR12 | 67% | 100% |
| | | | | | | | | | DR13 | 67% | 100% |
| | | | | | | | | | DR15 | 67% | 100% |
| | | | | | | | | | DR16 | 67% | 100% |
| | | | | | | | | | DR51 | 67% | 100% |
| | | | | | | | | | DR8 | 67% | 100% |
| | | | | | | | | | DR9 | 67% | 100% |
| | | | | | | | | | DR14 | 33% | 100% |

Table 25. Summary of the 581st Serum Exchange (Serum #1317-1320) by Luminex PRA - class II

| Method: Luminex-PRA | | | | | | | | | | | |
|---------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | | 3 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| DR10 | 67% | 100% | DQ7 | 67% | 100% | NEG | 33% | - | DQ4 | 67% | 100% |
| DR11 | 67% | 100% | DQ8 | 67% | 100% | DQ7 | 33% | 100% | DQ5 | 67% | 100% |
| DR12 | 67% | 100% | DQ9 | 67% | 100% | DQ8 | 33% | 100% | DQ6 | 67% | 100% |
| DR13 | 67% | 100% | DR11 | 67% | 100% | DQ9 | 33% | 100% | DR1 | 67% | 100% |
| DR14 | 67% | 100% | DR4 | 67% | 100% | DQA1*03 | 33% | 100% | DR10 | 67% | 100% |
| DR17 | 67% | 100% | DR8 | 67% | 100% | | | | DR103 | 67% | 100% |
| DR18 | 67% | 100% | DQ6 | 33% | 100% | | | | DR11 | 67% | 100% |
| DR52 | 67% | 100% | DQA1*03 | 33% | 100% | | | | DR12 | 67% | 100% |
| DR8 | 67% | 100% | DQA1*05 | 33% | 100% | | | | DR13 | 67% | 100% |
| DR9 | 67% | 100% | DR13 | 33% | 100% | | | | DR14 | 67% | 100% |
| DR1403 | 33% | 100% | DR16 | 33% | 100% | | | | DR15 | 67% | 100% |
| DR1404 | 33% | 100% | | | | | | | DR16 | 67% | 100% |
| DR53 | 33% | 100% | | | | | | | DR17 | 67% | 100% |
| | | | | | | | | | DR18 | 67% | 100% |
| | | | | | | | | | DR51 | 67% | 100% |
| | | | | | | | | | DR52 | 67% | 100% |
| | | | | | | | | | DR7 | 67% | 100% |
| | | | | | | | | | DR8 | 67% | 100% |
| | | | | | | | | | DR9 | 67% | 100% |
| | | | | | | | | | DPw1 | 33% | 100% |
| | | | | | | | | | DPw4 | 33% | 100% |
| | | | | | | | | | DPw5 | 33% | 100% |
| | | | | | | | | | DQ2 | 33% | 100% |
| | | | | | | | | | DQ7 | 33% | 100% |
| | | | | | | | | | DQA1*01 | 33% | 100% |
| | | | | | | | | | DQA1*02 | 33% | 100% |
| | | | | | | | | | DQA1*03 | 33% | 100% |
| | | | | | | | | | DQA1*04 | 33% | 100% |
| | | | | | | | | | DQA1*05 | 33% | 100% |
| | | | | | | | | | DQA1*06 | 33% | 100% |
| | | | | | | | | | DR1403 | 33% | 100% |
| | | | | | | | | | DR1404 | 33% | 100% |
| | | | | | | | | | DR4 | 33% | 100% |
| | | | | | | | | | DR53 | 33% | 100% |

Table 26. Summary of the 581st Serum Exchange (Serum #1317-1320) by Single Antigen - class II

| Method: Luminex - SAB | | | | | | | | | | | |
|-----------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|--------------------|-----------|-----------|
| *** Serum 1317 *** | | | *** Serum 1318 *** | | | *** Serum 1319 *** | | | *** Serum 1320 *** | | |
| 21 typing Labs | | | 21 typing Labs | | | 19 typing Labs | | | 21 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| DR14 | 95% | 100% | DQ7 | 100% | 100% | DQ8 | 58% | 100% | DP11 | 100% | 100% |
| DR11 | 90% | 100% | DQ8 | 100% | 100% | DQ7 | 52% | 100% | DP13 | 100% | 100% |
| DR12 | 90% | 100% | DQ9 | 100% | 100% | DQ9 | 47% | 100% | DPw5 | 100% | 100% |
| DR13 | 90% | 100% | DR11 | 100% | 100% | DQA1*03 | 42% | 0% | DQ4 | 100% | 100% |
| DR17 | 90% | 100% | DR4 | 100% | 100% | DQA1*05 | 21% | 100% | DQ6 | 100% | 100% |
| DR18 | 90% | 100% | DR8 | 100% | 100% | DQA1*06 | 16% | 100% | DR1 | 100% | 100% |
| DR8 | 90% | 100% | DR13 | 90% | 38% | DQ3 | 11% | 100% | DR10 | 100% | 100% |
| DR9 | 90% | 100% | DR16 | 76% | 100% | NEG | 11% | 100% | DR103 | 100% | 100% |
| DR53 | 90% | 94% | DQ6 | 57% | 33% | | | | DR11 | 100% | 100% |
| DR10 | 86% | 100% | DR53 | 52% | 100% | | | | DR12 | 100% | 100% |
| DR52 | 81% | 93% | DQA1*03 | 29% | 100% | | | | DR13 | 100% | 100% |
| DR7 | 38% | 100% | DR52 | 29% | 33% | | | | DR14 | 100% | 100% |
| DQ5 | 38% | 50% | DPw5 | 24% | 100% | | | | DR15 | 100% | 100% |
| DQ2 | 24% | 100% | DQ4 | 24% | 100% | | | | DR16 | 100% | 100% |
| DQA1*05 | 19% | 100% | DQA1*05 | 24% | 100% | | | | DR17 | 100% | 100% |
| DR1403 | 14% | 100% | DQA1*06 | 24% | 100% | | | | DR18 | 100% | 100% |
| DR1404 | 14% | 100% | DP14 | 19% | 100% | | | | DR51 | 100% | 100% |
| DQA1*01 | 10% | 100% | DP17 | 19% | 100% | | | | DR52 | 100% | 100% |
| DR3 | 10% | 100% | DPA1*02 | 19% | 100% | | | | DR53 | 100% | 100% |
| DQ6 | 5% | 100% | DR1404 | 19% | 100% | | | | DR7 | 100% | 100% |
| DQ7 | 5% | 100% | DP9 | 14% | 100% | | | | DR8 | 100% | 100% |
| DQ8 | 5% | 100% | DQA1*01 | 14% | 100% | | | | DR9 | 100% | 100% |
| DQ9 | 5% | 100% | DR15 | 14% | 100% | | | | DPw1 | 95% | 100% |
| DQA1*03 | 5% | 100% | DP10 | 10% | 100% | | | | DQ5 | 95% | 100% |
| DQA1*06 | 5% | 100% | DP11 | 10% | 100% | | | | DP19 | 90% | 100% |
| DR16 | 5% | 100% | DP13 | 10% | 100% | | | | DPw4 | 86% | 93% |
| DR4 | 5% | 100% | DP15 | 10% | 100% | | | | DP15 | 81% | 100% |
| DR5 | 5% | 100% | DPw1 | 10% | 100% | | | | DR4 | 81% | 64% |
| DR6 | 5% | 100% | DQ3 | 10% | 100% | | | | DP17 | 76% | 100% |
| NEG | 5% | 100% | DR12 | 10% | 100% | | | | DP23 | 76% | 100% |
| | | | DR14 | 10% | 100% | | | | DPw2 | 76% | 100% |
| | | | DR51 | 10% | 100% | | | | DP28 | 71% | 67% |
| | | | DP19 | 5% | 100% | | | | DQA1*05 | 67% | 100% |
| | | | DP28 | 5% | 100% | | | | DQ7 | 48% | 100% |
| | | | DPw3 | 5% | 100% | | | | DQA1*01 | 43% | 100% |

Table 26. Summary of the 581st Serum Exchange (Serum #1317-1320) by Single Antigen - class II

| Method: Luminex - SAB, cont. | | | | | |
|------------------------------|-----------|-----------|---------------------------|-----------|-----------|
| *** Serum 1318 *** | | | *** Serum 1320 *** | | |
| 23 typing Labs | | | 23 typing Labs | | |
| Antigen | Consensus | Inclusion | Antigen | Consensus | Inclusion |
| DPw6 | 5% | 100% | DP9 | 38% | 100% |
| DQA1*02 | 5% | 100% | DPA1*02 | 38% | 100% |
| DR103 | 5% | 100% | DPw3 | 38% | 100% |
| | | | DQ8 | 38% | 100% |
| | | | DQA1*04 | 38% | 100% |
| | | | DP14 | 33% | 100% |
| | | | DPA1*01 | 33% | 100% |
| | | | DPA1*04 | 33% | 100% |
| | | | DPw6 | 33% | 100% |
| | | | DQ9 | 33% | 100% |
| | | | DQA1*06 | 33% | 100% |
| | | | DP18 | 29% | 100% |
| | | | DP20 | 29% | 100% |
| | | | DP401 | 29% | 100% |
| | | | DQ2 | 29% | 80% |
| | | | DQA1*03 | 24% | 100% |
| | | | DR1404 | 19% | 100% |
| | | | DP10 | 14% | 100% |
| | | | DPA1*03 | 14% | 100% |
| | | | DR1403 | 14% | 100% |
| | | | DR3 | 10% | 100% |
| | | | DP26 | 5% | 100% |
| | | | DPA1*05 | 5% | 100% |
| | | | DQ1 | 5% | 100% |
| | | | DQA1*02 | 5% | 100% |
| | | | DR2 | 5% | 100% |
| | | | DR5 | 5% | 100% |
| | | | DR6 | 5% | 100% |

Table 27. Individual laboratory results for Serum #1317 - 1320 by NIH-Standard - class I

| Ctr | **** Serum 1317 **** | | | | **** Serum 1318 **** | | | | **** Serum 1319 **** | | | | **** Serum 1320 **** | | | | Method |
|-----|----------------------|-----|--|-------|----------------------|-----|--|-------|----------------------|-----|----|-------|----------------------|-----|--|-------|--------|
| | % POS | A29 | | Other | % POS | A66 | | Other | % POS | B27 | B7 | Other | % POS | B18 | | Other | |
| 786 | | + | | | | + | | | | + | + | | | + | | | STD |

STD = NIH-standard

Table 28. Individual laboratory results for Serum #1317 - 1320 by Antiglobulin - class I

| Ctr | **** Serum 1317 **** | | | | | | | | | | | **** Serum 1318 **** | | | **** Serum 1319 **** | | | | | | | | | | **** Serum 1320 **** | | | | | | | | | Method | | | | |
|-----|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----------------------|-------|-----|----------------------|-------|-----|-----|----|-----|-----|-----|-----|-----|----------------------|-------|-------|-----|----|-----|-----|-----|-----|--------|-----|-----|--------------|--------------|
| | % POS | A29 | A36 | B42 | B49 | B53 | B56 | B70 | B55 | B35 | A1 | Other | % POS | A66 | Other | % POS | B27 | B42 | B7 | B48 | B56 | B60 | B61 | B81 | B55 | Other | % POS | B18 | A3 | B35 | B37 | B38 | B41 | | B44 | B51 | B8 | Other |
| 774 | 47 | + | + | + | + | + | + | + | + | + | + | | 100 | | | 55 | + | + | + | + | + | + | + | + | + | | 90 | + | + | + | + | + | + | + | + | + | + | Antiglobulin |
| 786 | | + | | | | | | | | | | | + | | | | + | + | + | | | | | | | | + | | | | | | | | | | Antiglobulin | |

Table 29. Individual laboratory results for Serum #1317 - 1320 by C1q - class I

| **** Serum 1317 **** | | | | | | | | | | | | | | | | | **** Serum 1318 **** | | | | | | | | | | | |
|----------------------|-------|----|-----|-----|-----|-----|--|--|--|--|--|--|--|--|--|--|----------------------|-------|-----|-----|-----|-----|-----|-----|-------|-------|--------|-----|
| Ctr | % POS | A1 | A29 | A36 | A30 | B75 | | | | | | | | | | | Other | % POS | A66 | A11 | A25 | A26 | A34 | A43 | A6601 | Other | Method | |
| 786 | | + | + | | + | | | | | | | | | | | | | | | | | | | | + | | | C1q |
| 2400 | | + | + | + | | + | | | | | | | | | | | | | + | + | + | + | + | + | | | | C1q |
| 3753 | | + | + | + | | | | | | | | | | | | | | | + | | | | | | | | | C1q |

| **** Serum 1319 **** | | | | | | | | | | | | | | | | | **** Serum 1320 **** | | | | | | | | | | | | | |
|----------------------|-------|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|----------------------|-------|-------|-------|-------|-------|-----|-----|-----|-----|-----|--|-------------------|--------|
| Ctr | % POS | B42 | B54 | B56 | B67 | B7 | B73 | B27 | B48 | B55 | B60 | B61 | B81 | B82 | A66 | A6602 | B2705 | B2708 | B8101 | B8201 | Other | % POS | B18 | B51 | B64 | A23 | A24 | | Other | Method |
| 786 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | + | + | | | | | C1q |
| 2400 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | + | + | + | + | + | | B78,B53,B54,B65 > | C1q |
| 3753 | | + | + | + | + | + | + | + | | + | | | + | + | | | | | | | | | + | + | + | | | | | C1q |

Table 30. Individual laboratory results for Serum #1317 - 1320 by Luminex PRA - class I

| **** Serum 1317 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------------|-------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|-----|-----|-----|-----|-----|-----|-----|-------------------|---------|
| Ctr | % POS | A1 | A26 | A29 | A30 | A36 | A80 | B35 | B42 | B49 | B53 | B56 | B58 | B62 | B63 | B67 | B71 | B72 | A2 | A3 | A43 | A68 | B39 | B41 | B44 | B50 | B54 | Other | Method |
| 2400 | 89 | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX-PRA |
| 3753 | 90 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | | | | | + | B7 | LMX-PRA |
| 8043 | 23 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | + | + | + | + | | B82,B75,B55,B77 > | LMX-PRA |

| **** Serum 1318 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------------|-------|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|----|----|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------------------|---------|
| Ctr | % POS | A11 | A25 | A26 | A29 | A3 | A30 | A31 | A32 | A33 | A34 | A66 | A68 | B7 | B8 | B81 | A1 | A36 | A43 | A69 | A74 | A80 | B15 | B27 | B39 | B40 | B41 | Other | Method |
| 2400 | 89 | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX-PRA |
| 3753 | 96 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | | | LMX-PRA |
| 8043 | 33 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | B48,B44,B82,B703 > | LMX-PRA |

| **** Serum 1319 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|----|-----|-------|------|-------|------|-----|--|-------|--------|---------|
| Ctr | % POS | B13 | B27 | B42 | B47 | B48 | B54 | B55 | B56 | B57 | B60 | B61 | B63 | B67 | B7 | B73 | B81 | B82 | A3 | A66 | B2708 | B703 | B8201 | Cw15 | Cw3 | | Other | Method | |
| 2400 | 62 | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX-PRA |
| 3753 | 62 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | LMX-PRA |
| 8043 | 27 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | LMX-PRA |

| **** Serum 1320 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|----|----|------|-----|-----|-------|-------------------|---------|
| Ctr | % POS | B18 | B35 | B37 | B38 | B44 | B45 | B51 | B52 | B53 | B54 | B59 | B62 | B64 | B65 | B71 | B72 | B77 | B78 | B8 | B82 | A1 | A2 | A203 | A23 | A24 | A2403 | Other | Method |
| 2400 | 100 | | | | | | | | | | | | | | | | | | | | | | | | | | | | LMX-PRA |
| 3753 | 96 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | B7,B55,B81 | LMX-PRA |
| 8043 | 58 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | B60,B61,A66,B50 > | LMX-PRA |

Table 33. Individual laboratory results for Serum #1319 by Single Antigen - class I

| | | **** Serum 1319 **** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------|-------|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|------|------|-----|-----|-------|-------|-----|------|-------|-------|-----|------|-------|------------------|---------------------|---------|---------|
| Ctr | % POS | B13 | B42 | B47 | B54 | B55 | B56 | B57 | B60 | B61 | B63 | B67 | B7 | B73 | B82 | Cw2 | B27 | B48 | B81 | Cw9 | Cw10 | Cw15 | B46 | A66 | A6602 | B2708 | Cw1 | Cw14 | B2705 | B8101 | A25 | Cw16 | Other | Method | | | |
| 615 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | | | | A*66:02 | LMX-SAB | | |
| 725 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | | | | | | LMX-SAB | |
| 774 | 61 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | B64 | LMX-SAB | | |
| 786 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | + | + | | | | B8201 | LMX-SAB | | |
| 910 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | | | | | | | LMX-SAB | |
| 2400 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | | LMX-SAB | |
| 3224 | 29 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | + | + | | | | | | LMX-SAB | |
| 3753 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | | | | | | LMX-SAB | |
| 3766 | 76 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | + | | + | + | | | | | | LMX-SAB | |
| 3808 | 23 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | | | | | | | | LMX-SAB | |
| 3966 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | + | | | | | | | | | LMX-SAB |
| 4322 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | + | + | | | | + | + | | Cw4,B52,B75,A32 > | LMX-SAB | |
| 5219 | 21 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | + | | + | + | | | | B40,B703,B22,B7C | LMX-SAB | | |
| 5462 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | + | + | | | | | B8201 | LMX-SAB | |
| 6649 | 30 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | | LMX-SAB | |
| 8082 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | + | + | | | | | | | B52,A32,B64,Cw17 | LMX-SAB | |
| 8086 | 30 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | + | | LMX-SAB | |
| 8090 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | + | | | | | | | | LMX-SAB | |
| 8098 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | | | | | | | | | B703,Bw4,Bw6,B12C > | LMX-SAB | |
| 8100 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | + | + | | | | | | | | LMX-SAB | |
| 8103 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | + | + | | | + | + | | | | B40,B15,B703,Cw3 | LMX-SAB | |
| 8112 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | | LMX-SAB | |
| 8125 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | + | + | | | | | | B39 | LMX-SAB | |

Table 34. Individual laboratory results for Serum #1320 by Single Antigen - class I, cont.

| **** Serum 1320 **** | | | | | | | | | | | | | | |
|----------------------|-------|-----|-----|-------|-------|-------|------|-------|-------|-----|-----|---------------------------------|-------------------|---------|
| Ctr | % POS | B56 | B13 | A2403 | A6602 | B3901 | A203 | A6601 | B2708 | B49 | Bw6 | Other | Method | |
| 615 | | + | + | | | | | | | | | B*13:02 | LMX-SAB | |
| 725 | | | | | | | | | | | | | LMX-SAB | |
| 774 | 100 | | | | | | | | | | | | LMX-SAB | |
| 786 | | + | + | + | + | + | + | + | + | + | | B8101,B8201 | LMX-SAB | |
| 910 | | | | | | | | | | | | | LMX-SAB | |
| 2400 | | | | | | | | | | | | | LMX-SAB | |
| 3224 | 61 | + | + | + | + | | | + | + | | | | LMX-SAB | |
| 3753 | | | | | | | | | + | | + | | LMX-SAB | |
| 3766 | 100 | | | | + | + | + | + | + | | | B7801,B8201,A*29:02, B*27:08 | LMX-SAB | |
| 3808 | | | | + | + | | | | | | | B7801 | LMX-SAB | |
| 3966 | | | | | | | | | | | | | LMX-SAB | |
| 4322 | | + | + | | | | | | | + | + | Cw4,Cw6,A11,B47 > | LMX-SAB | |
| 5219 | 32 | | | + | | + | + | | | | | + | A9,B5,A28,B12 > | LMX-SAB |
| 5462 | | | | + | + | + | | + | | | | | B8101,B7801,B8201 | LMX-SAB |
| 6649 | 62 | | | | | | | | | | | | LMX-SAB | |
| 8082 | | + | + | | | | | | | | + | | LMX-SAB | |
| 8086 | 54 | | | | | | | | | | | | LMX-SAB | |
| 8090 | | + | + | | | | | | | | + | | LMX-SAB | |
| 8098 | | | | + | | + | + | | | | + | Bw4,B12C,B5C,B8C > | LMX-SAB | |
| 8100 | | + | + | | | | | | | | | B8C,A2C | LMX-SAB | |
| 8103 | | + | | + | + | + | + | + | + | | | B40,B15,B703,B14 > | LMX-SAB | |
| 8112 | | | | | | | | | | | | | LMX-SAB | |
| 8125 | | + | + | | | | | | | | | Cw18,B4005 | LMX-SAB | |

Table 35. Individual laboratory results for Serum #1317 - 1320 by C1q - class II

| | | **** Serum 1317 **** | | | | **** Serum 1318 **** | | | | | | **** Serum 1319 **** | | | | **** Serum 1320 **** | | | | | | | | | | | | | | | | | | | |
|------|-------|----------------------|--|-------|-------|----------------------|------|------|-----|-----|-----|----------------------|-------|--|--|----------------------|-------|-----|-----|-----|-----|------|-------|------|------|------|------|------|------|-----|-----|------|-------|--------|-----|
| Ctr | % POS | | | Other | % POS | DQ7 | DR11 | DR13 | DR8 | DQ8 | DQ9 | Other | % POS | | | Other | % POS | DQ4 | DQ5 | DQ6 | DR1 | DR10 | DR103 | DR11 | DR12 | DR13 | DR15 | DR16 | DR51 | DR8 | DR9 | DR14 | Other | Method | |
| 2400 | 0 | | | | | + | + | + | + | + | + | | 0 | | | | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | C1q |
| 3753 | 0 | | | | | + | + | + | + | | | DRB1*13:03 | 0 | | | | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | C1q |

Table 37. Individual laboratory results for Serum #1317 by Single Antigen - class II

| **** Serum 1317 **** | | | | | | | | | | | | | | | | | |
|----------------------|-------|------|------|------|------|------|------|-----|-----|------|------|------|-----|-----|-----|---------------------------------------|---------|
| Ctr | % POS | DR14 | DR11 | DR12 | DR13 | DR17 | DR18 | DR8 | DR9 | DR53 | DR10 | DR52 | DR7 | DQ5 | DQ2 | Other | Method |
| 615 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | DQB1*05:02 | LMX-SAB |
| 774 | 89 | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX-SAB |
| 910 | | + | + | + | + | + | + | + | + | + | + | + | + | | | DQB1*05:02 | LMX-SAB |
| 2400 | | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX-SAB |
| 3224 | 23 | + | + | + | + | + | + | + | + | + | + | + | + | | + | DQB1*05:02 | LMX-SAB |
| 3753 | | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX-SAB |
| 3766 | 92 | + | + | + | + | + | + | + | + | + | + | | | | | DQB1*05:02, DRB3*03:01, DRB3*02:02 | LMX-SAB |
| 3808 | 0 | | | | | | | | | | | | | | | | LMX-SAB |
| 3966 | | + | + | + | + | + | + | + | + | + | + | + | | + | | DR4,DR16,DQ7,DQ8 > | LMX-SAB |
| 4322 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | DQ6,DQA1*01,DQA1*05 | LMX-SAB |
| 5219 | 19 | + | + | + | + | + | + | + | + | + | + | | | | | DR3,DR5,DR6,DR1403 > | LMX-SAB |
| 5462 | | + | + | + | + | + | + | + | + | + | + | + | | | | | LMX-SAB |
| 6649 | 24 | + | + | + | + | + | + | + | + | + | + | + | + | | | | LMX-SAB |
| 8082 | | + | + | + | + | + | + | + | + | + | + | + | + | + | | DQA1*05 | LMX-SAB |
| 8086 | 19 | + | + | + | + | + | + | + | + | + | + | + | + | + | | | LMX-SAB |
| 8090 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | DQA1*05 | LMX-SAB |
| 8098 | | + | + | + | + | + | + | + | + | + | + | + | | | | DR1403,DR1404 | LMX-SAB |
| 8100 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | | LMX-SAB |
| 8103 | | + | + | + | + | + | + | + | + | + | + | + | | | | DR3,DR1403,DR1404 | LMX-SAB |
| 8112 | | + | | | | | | | | | | | | | | | LMX-SAB |
| 8125 | | + | + | + | + | + | + | + | + | + | + | + | | + | | | LMX-SAB |

Table 38. Individual laboratory results for Serum #1318 - 1319 by Single Antigen - class II

| **** Serum 1318 **** | | | | | | | | | | | | | | | | **** Serum 1319 **** | | | | | | | | | | |
|----------------------|-------|-----|-----|-----|------|-----|-----|------|------|-----|------|---------|------|------|-----|----------------------|---------|---|-------|-----|-----|-----|---------|---------|------------|---------|
| Ctr | % POS | DQ7 | DQ8 | DQ9 | DR11 | DR4 | DR8 | DR13 | DR16 | DQ6 | DR53 | DQA1*03 | DR52 | DPw5 | DQ4 | DQA1*05 | DQA1*06 | Other | % POS | DQ8 | DQ7 | DQ9 | DQA1*03 | DQA1*05 | Other | Method |
| 615 | | + | + | + | + | + | + | + | + | + | + | | | | + | | | DPA1*02, DRB1*13:03 | | + | + | + | | | | LMX-SAB |
| 774 | 57 | + | + | + | + | + | + | + | | + | | | | | | | | | 0 | | | | + | | | LMX-SAB |
| 910 | | + | + | + | + | + | + | | + | | + | | | | | | | DQA1*03:03, DQB1*06:01, DQB1*06:03, DQB1*06:09, DRB1*13:03 | | + | + | + | | | | LMX-SAB |
| 2400 | | + | + | + | + | + | + | + | + | + | | | | | | | | | | + | + | + | | | | LMX-SAB |
| 3224 | 28 | + | + | + | + | + | + | + | + | + | + | | | | | | | DQA1*01:03, DQA1*03:02, DQA1*03:03 | 8 | + | + | + | | | DQA1*03:02 | LMX-SAB |
| 3753 | | + | + | + | + | + | + | + | + | + | + | | | | | | | DRB1*13:03 | | + | + | + | | | | LMX-SAB |
| 3766 | 65 | + | + | + | + | + | + | | + | | | + | | | | + | + | DRB1*13:03, DQA1*01:03, DQA1*06:01, DQA1*05:03, DQA1*05:05, DQA1*03:02> | 0 | | | | | | | LMX-SAB |
| 3808 | 23 | + | + | + | + | + | + | + | | | | | | | | | | DR1404 | 5 | | | | + | | DQ3 | LMX-SAB |
| 3966 | | + | + | + | + | + | + | + | + | + | + | + | | | | + | + | DQA1*01 | 0 | | | | | | | LMX-SAB |
| 4322 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | DR12,DR15,DR51,DPw1 > | | + | + | + | + | + | DQA1*06 | LMX-SAB |
| 5219 | 22 | + | + | + | + | + | + | + | | | | | | | | | | DR1404,DQ3 | 5 | | | | | | | LMX-SAB |
| 5462 | | + | + | + | + | + | + | + | + | + | | | | | | | | | | + | + | + | | | | LMX-SAB |
| 6649 | 32 | + | + | + | + | + | + | + | + | + | + | | | | | | | | 8 | | | | + | + | DQA1*06 | LMX-SAB |
| 8082 | | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | DR103,DR12,DR15,DR51 > | | + | + | + | + | + | DQA1*06 | LMX-SAB |
| 8086 | 200 | + | + | + | + | + | + | + | + | + | + | + | + | | | | | | | | | | | | | LMX-SAB |
| 8090 | | + | + | + | + | + | + | + | + | + | + | + | + | + | | | | DP9,DP17,DP14 | | | | | + | + | | LMX-SAB |
| 8098 | | + | + | + | + | + | + | + | + | | | | + | + | | | | DR1404,DR15,DPw1,DP11 > | | + | | | | | | LMX-SAB |
| 8100 | | + | + | + | + | + | + | + | + | + | + | | + | + | + | | | DPw3 | | + | + | + | | | | LMX-SAB |
| 8103 | | + | + | + | + | + | + | + | | | | | | | | | | DR14,DR1404,DQ3 | | + | + | | + | | DQ3 | LMX-SAB |
| 8112 | | + | + | + | + | + | + | + | | | | + | | | | | | | | | | | + | | | LMX-SAB |
| 8125 | | + | + | + | + | + | + | + | + | + | + | | | | + | | | DR14 | | | | | | | | LMX-SAB |

Table 40. Individual laboratory results for Serum #1320 by Single Antigen - class II, cont.

| **** Serum 1320 **** | | | | | | | | | |
|----------------------|-------|-----|---------|--------|------|---------|--------|--|---------|
| Ctr | DP401 | DQ2 | DQA1*03 | DR1404 | DP10 | DPA1*03 | DR1403 | Other | Method |
| 615 | + | | | | | | | DRB1*04:02, DPB1*04:01, DPB1*02:01 | LMX-SAB |
| 774 | | + | | | | | | | LMX-SAB |
| 910 | | | | | | | | DRB1*04:02, DQA1*04:01, DQA1*05:01, DQA1*05:03, DQA1*05:05, DQA1*06:01, DPA1*01:03 | LMX-SAB |
| 2400 | | | | | | | | | LMX-SAB |
| 3224 | | | | | | + | | DRB1*04:02 | LMX-SAB |
| 3753 | + | | | | | | | DRB1*04:02 | LMX-SAB |
| 3766 | | | | | | | | DRB1*04:02, DPA1*01:03, DQA1*05:05, DQA1*05:01, DQA1*05:03, DQA1*06:01> | LMX-SAB |
| 3808 | + | | | + | | | + | | LMX-SAB |
| 3966 | | + | + | | | | | | LMX-SAB |
| 4322 | | + | + | | + | + | | DQA1*02 | LMX-SAB |
| 5219 | + | | | + | | | + | DR2,DR3,DR5,DR6 > | LMX-SAB |
| 5462 | + | | | | | | | | LMX-SAB |
| 6649 | | | | | | | | | LMX-SAB |
| 8082 | | | + | | + | | | | LMX-SAB |
| 8086 | | + | | | | | | | LMX-SAB |
| 8090 | | | | | | | | | LMX-SAB |
| 8098 | | | + | + | | + | | | LMX-SAB |
| 8100 | | + | | | | | | | LMX-SAB |
| 8103 | + | | | + | | | + | DR3,DPA1*05 | LMX-SAB |
| 8112 | | | + | | | | | | LMX-SAB |
| 8125 | | + | | | + | | | DP26 | LMX-SAB |